1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Drug Reprofiling Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Orally 1.2.3 Intravenously 1.3 Market by Application 1.3.1 Global Drug Reprofiling Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Central Nervous Disorders 1.3.3 Cardiovascular Disorders 1.3.4 Oncology 1.3.5 others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Drug Reprofiling Market Perspective (2016-2027) 2.2 Drug Reprofiling Growth Trends by Regions 2.2.1 Drug Reprofiling Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Drug Reprofiling Historic Market Share by Regions (2016-2021) 2.2.3 Drug Reprofiling Forecasted Market Size by Regions (2022-2027) 2.3 Drug Reprofiling Industry Dynamic 2.3.1 Drug Reprofiling Market Trends 2.3.2 Drug Reprofiling Market Drivers 2.3.3 Drug Reprofiling Market Challenges 2.3.4 Drug Reprofiling Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Drug Reprofiling Players by Revenue 3.1.1 Global Top Drug Reprofiling Players by Revenue (2016-2021) 3.1.2 Global Drug Reprofiling Revenue Market Share by Players (2016-2021) 3.2 Global Drug Reprofiling Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Drug Reprofiling Revenue 3.4 Global Drug Reprofiling Market Concentration Ratio 3.4.1 Global Drug Reprofiling Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Drug Reprofiling Revenue in 2020 3.5 Drug Reprofiling Key Players Head office and Area Served 3.6 Key Players Drug Reprofiling Product Solution and Service 3.7 Date of Enter into Drug Reprofiling Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Drug Reprofiling Breakdown Data by Type 4.1 Global Drug Reprofiling Historic Market Size by Type (2016-2021) 4.2 Global Drug Reprofiling Forecasted Market Size by Type (2022-2027) 5 Drug Reprofiling Breakdown Data by Application 5.1 Global Drug Reprofiling Historic Market Size by Application (2016-2021) 5.2 Global Drug Reprofiling Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Drug Reprofiling Market Size (2016-2027) 6.2 North America Drug Reprofiling Market Size by Type 6.2.1 North America Drug Reprofiling Market Size by Type (2016-2021) 6.2.2 North America Drug Reprofiling Market Size by Type (2022-2027) 6.2.3 North America Drug Reprofiling Market Size by Type (2016-2027) 6.3 North America Drug Reprofiling Market Size by Application 6.3.1 North America Drug Reprofiling Market Size by Application (2016-2021) 6.3.2 North America Drug Reprofiling Market Size by Application (2022-2027) 6.3.3 North America Drug Reprofiling Market Size by Application (2016-2027) 6.4 North America Drug Reprofiling Market Size by Country 6.4.1 North America Drug Reprofiling Market Size by Country (2016-2021) 6.4.2 North America Drug Reprofiling Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Drug Reprofiling Market Size (2016-2027) 7.2 Europe Drug Reprofiling Market Size by Type 7.2.1 Europe Drug Reprofiling Market Size by Type (2016-2021) 7.2.2 Europe Drug Reprofiling Market Size by Type (2022-2027) 7.2.3 Europe Drug Reprofiling Market Size by Type (2016-2027) 7.3 Europe Drug Reprofiling Market Size by Application 7.3.1 Europe Drug Reprofiling Market Size by Application (2016-2021) 7.3.2 Europe Drug Reprofiling Market Size by Application (2022-2027) 7.3.3 Europe Drug Reprofiling Market Size by Application (2016-2027) 7.4 Europe Drug Reprofiling Market Size by Country 7.4.1 Europe Drug Reprofiling Market Size by Country (2016-2021) 7.4.2 Europe Drug Reprofiling Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Drug Reprofiling Market Size (2016-2027) 8.2 Asia-Pacific Drug Reprofiling Market Size by Type 8.2.1 Asia-Pacific Drug Reprofiling Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Drug Reprofiling Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Drug Reprofiling Market Size by Type (2016-2027) 8.3 Asia-Pacific Drug Reprofiling Market Size by Application 8.3.1 Asia-Pacific Drug Reprofiling Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Drug Reprofiling Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Drug Reprofiling Market Size by Application (2016-2027) 8.4 Asia-Pacific Drug Reprofiling Market Size by Region 8.4.1 Asia-Pacific Drug Reprofiling Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Drug Reprofiling Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Drug Reprofiling Market Size (2016-2027) 9.2 Latin America Drug Reprofiling Market Size by Type 9.2.1 Latin America Drug Reprofiling Market Size by Type (2016-2021) 9.2.2 Latin America Drug Reprofiling Market Size by Type (2022-2027) 9.2.3 Latin America Drug Reprofiling Market Size by Type (2016-2027) 9.3 Latin America Drug Reprofiling Market Size by Application 9.3.1 Latin America Drug Reprofiling Market Size by Application (2016-2021) 9.3.2 Latin America Drug Reprofiling Market Size by Application (2022-2027) 9.3.3 Latin America Drug Reprofiling Market Size by Application (2016-2027) 9.4 Latin America Drug Reprofiling Market Size by Country 9.4.1 Latin America Drug Reprofiling Market Size by Country (2016-2021) 9.4.2 Latin America Drug Reprofiling Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Drug Reprofiling Market Size (2016-2027) 10.2 Middle East & Africa Drug Reprofiling Market Size by Type 10.2.1 Middle East & Africa Drug Reprofiling Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Drug Reprofiling Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Drug Reprofiling Market Size by Type (2016-2027) 10.3 Middle East & Africa Drug Reprofiling Market Size by Application 10.3.1 Middle East & Africa Drug Reprofiling Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Drug Reprofiling Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Drug Reprofiling Market Size by Application (2016-2027) 10.4 Middle East & Africa Drug Reprofiling Market Size by Country 10.4.1 Middle East & Africa Drug Reprofiling Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Drug Reprofiling Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Novartis AG 11.1.1 Novartis AG Company Details 11.1.2 Novartis AG Business Overview 11.1.3 Novartis AG Drug Reprofiling Introduction 11.1.4 Novartis AG Revenue in Drug Reprofiling Business (2016-2021) 11.1.5 Novartis AG Recent Development 11.2 Abbott Healthcare 11.2.1 Abbott Healthcare Company Details 11.2.2 Abbott Healthcare Business Overview 11.2.3 Abbott Healthcare Drug Reprofiling Introduction 11.2.4 Abbott Healthcare Revenue in Drug Reprofiling Business (2016-2021) 11.2.5 Abbott Healthcare Recent Development 11.3 Pfizer 11.3.1 Pfizer Company Details 11.3.2 Pfizer Business Overview 11.3.3 Pfizer Drug Reprofiling Introduction 11.3.4 Pfizer Revenue in Drug Reprofiling Business (2016-2021) 11.3.5 Pfizer Recent Development 11.4 Johnson & Johnson 11.4.1 Johnson & Johnson Company Details 11.4.2 Johnson & Johnson Business Overview 11.4.3 Johnson & Johnson Drug Reprofiling Introduction 11.4.4 Johnson & Johnson Revenue in Drug Reprofiling Business (2016-2021) 11.4.5 Johnson & Johnson Recent Development 11.5 Hoffmann-La Roche 11.5.1 Hoffmann-La Roche Company Details 11.5.2 Hoffmann-La Roche Business Overview 11.5.3 Hoffmann-La Roche Drug Reprofiling Introduction 11.5.4 Hoffmann-La Roche Revenue in Drug Reprofiling Business (2016-2021) 11.5.5 Hoffmann-La Roche Recent Development 11.6 Sandoz 11.6.1 Sandoz Company Details 11.6.2 Sandoz Business Overview 11.6.3 Sandoz Drug Reprofiling Introduction 11.6.4 Sandoz Revenue in Drug Reprofiling Business (2016-2021) 11.6.5 Sandoz Recent Development 11.7 Mylan Inc. 11.7.1 Mylan Inc. Company Details 11.7.2 Mylan Inc. Business Overview 11.7.3 Mylan Inc. Drug Reprofiling Introduction 11.7.4 Mylan Inc. Revenue in Drug Reprofiling Business (2016-2021) 11.7.5 Mylan Inc. Recent Development 11.8 Teva Pharmaceuticals 11.8.1 Teva Pharmaceuticals Company Details 11.8.2 Teva Pharmaceuticals Business Overview 11.8.3 Teva Pharmaceuticals Drug Reprofiling Introduction 11.8.4 Teva Pharmaceuticals Revenue in Drug Reprofiling Business (2016-2021) 11.8.5 Teva Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Drug Reprofiling Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Orally Table 3. Key Players of Intravenously Table 4. Global Drug Reprofiling Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 5. Global Drug Reprofiling Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Drug Reprofiling Market Size by Regions (2016-2021) & (US$ Million) Table 7. Global Drug Reprofiling Market Share by Regions (2016-2021) Table 8. Global Drug Reprofiling Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 9. Global Drug Reprofiling Market Share by Regions (2022-2027) Table 10. Drug Reprofiling Market Trends Table 11. Drug Reprofiling Market Drivers Table 12. Drug Reprofiling Market Challenges Table 13. Drug Reprofiling Market Restraints Table 14. Global Drug Reprofiling Revenue by Players (2016-2021) & (US$ Million) Table 15. Global Drug Reprofiling Market Share by Players (2016-2021) Table 16. Global Top Drug Reprofiling Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drug Reprofiling as of 2020) Table 17. Ranking of Global Top Drug Reprofiling Companies by Revenue (US$ Million) in 2020 Table 18. Global 5 Largest Players Market Share by Drug Reprofiling Revenue (CR5 and HHI) & (2016-2021) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Drug Reprofiling Product Solution and Service Table 21. Date of Enter into Drug Reprofiling Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Drug Reprofiling Market Size by Type (2016-2021) (US$ Million) Table 24. Global Drug Reprofiling Revenue Market Share by Type (2016-2021) Table 25. Global Drug Reprofiling Forecasted Market Size by Type (2022-2027) (US$ Million) Table 26. Global Drug Reprofiling Revenue Market Share by Type (2022-2027) & (US$ Million) Table 27. Global Drug Reprofiling Market Size Share by Application (2016-2021) & (US$ Million) Table 28. Global Drug Reprofiling Revenue Market Share by Application (2016-2021) Table 29. Global Drug Reprofiling Forecasted Market Size by Application (2022-2027) (US$ Million) Table 30. Global Drug Reprofiling Revenue Market Share by Application (2022-2027) & (US$ Million) Table 31. North America Drug Reprofiling Market Size by Type (2016-2021) (US$ Million) Table 32. North America Drug Reprofiling Market Size by Type (2022-2027) & (US$ Million) Table 33. North America Drug Reprofiling Market Size by Application (2016-2021) (US$ Million) Table 34. North America Drug Reprofiling Market Size by Application (2022-2027) & (US$ Million) Table 35. North America Drug Reprofiling Market Size by Country (2016-2021) & (US$ Million) Table 36. North America Drug Reprofiling Market Size by Country (2022-2027) & (US$ Million) Table 37. Europe Drug Reprofiling Market Size by Type (2016-2021) (US$ Million) Table 38. Europe Drug Reprofiling Market Size by Type (2022-2027) & (US$ Million) Table 39. Europe Drug Reprofiling Market Size by Application (2016-2021) (US$ Million) Table 40. Europe Drug Reprofiling Market Size by Application (2022-2027) & (US$ Million) Table 41. Europe Drug Reprofiling Market Size by Country (2016-2021) & (US$ Million) Table 42. Europe Drug Reprofiling Market Size by Country (2022-2027) & (US$ Million) Table 43. Asia-Pacific Drug Reprofiling Market Size by Type (2016-2021) (US$ Million) Table 44. Asia-Pacific Drug Reprofiling Market Size by Type (2022-2027) & (US$ Million) Table 45. Asia-Pacific Drug Reprofiling Market Size by Application (2016-2021) (US$ Million) Table 46. Asia-Pacific Drug Reprofiling Market Size by Application (2022-2027) & (US$ Million) Table 47. Asia-Pacific Drug Reprofiling Market Size by Region (2016-2021) & (US$ Million) Table 48. Asia-Pacific Drug Reprofiling Market Size by Region (2022-2027) & (US$ Million) Table 49. Latin America Drug Reprofiling Market Size by Type (2016-2021) (US$ Million) Table 50. Latin America Drug Reprofiling Market Size by Type (2022-2027) & (US$ Million) Table 51. Latin America Drug Reprofiling Market Size by Application (2016-2021) (US$ Million) Table 52. Latin America Drug Reprofiling Market Size by Application (2022-2027) & (US$ Million) Table 53. Latin America Drug Reprofiling Market Size by Country (2016-2021) & (US$ Million) Table 54. Latin America Drug Reprofiling Market Size by Country (2022-2027) & (US$ Million) Table 55. Middle East & Africa Drug Reprofiling Market Size by Type (2016-2021) (US$ Million) Table 56. Middle East & Africa Drug Reprofiling Market Size by Type (2022-2027) & (US$ Million) Table 57. Middle East & Africa Drug Reprofiling Market Size by Application (2016-2021) (US$ Million) Table 58. Middle East & Africa Drug Reprofiling Market Size by Application (2022-2027) & (US$ Million) Table 59. Middle East & Africa Drug Reprofiling Market Size by Country (2016-2021) & (US$ Million) Table 60. Middle East & Africa Drug Reprofiling Market Size by Country (2022-2027) & (US$ Million) Table 61. Novartis AG Company Details Table 62. Novartis AG Business Overview Table 63. Novartis AG Drug Reprofiling Product Table 64. Novartis AG Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 65. Novartis AG Recent Development Table 66. Abbott Healthcare Company Details Table 67. Abbott Healthcare Business Overview Table 68. Abbott Healthcare Drug Reprofiling Product Table 69. Abbott Healthcare Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 70. Abbott Healthcare Recent Development Table 71. Pfizer Company Details Table 72. Pfizer Business Overview Table 73. Pfizer Drug Reprofiling Product Table 74. Pfizer Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 75. Pfizer Recent Development Table 76. Johnson & Johnson Company Details Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Drug Reprofiling Product Table 79. Johnson & Johnson Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 80. Johnson & Johnson Recent Development Table 81. Hoffmann-La Roche Company Details Table 82. Hoffmann-La Roche Business Overview Table 83. Hoffmann-La Roche Drug Reprofiling Product Table 84. Hoffmann-La Roche Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 85. Hoffmann-La Roche Recent Development Table 86. Sandoz Company Details Table 87. Sandoz Business Overview Table 88. Sandoz Drug Reprofiling Product Table 89. Sandoz Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 90. Sandoz Recent Development Table 91. Mylan Inc. Company Details Table 92. Mylan Inc. Business Overview Table 93. Mylan Inc. Drug Reprofiling Product Table 94. Mylan Inc. Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 95. Mylan Inc. Recent Development Table 96. Teva Pharmaceuticals Company Details Table 97. Teva Pharmaceuticals Business Overview Table 98. Teva Pharmaceuticals Revenue in Drug Reprofiling Business (2016-2021) & (US$ Million) Table 99. Teva Pharmaceuticals Recent Development Table 100. Research Programs/Design for This Report Table 101. Key Data Information from Secondary Sources Table 102. Key Data Information from Primary Sources List of Figures Figure 1. Global Drug Reprofiling Market Share by Type: 2020 VS 2027 Figure 2. Orally Features Figure 3. Intravenously Features Figure 4. Global Drug Reprofiling Market Share by Application: 2020 VS 2027 Figure 5. Central Nervous Disorders Case Studies Figure 6. Cardiovascular Disorders Case Studies Figure 7. Oncology Case Studies Figure 8. others Case Studies Figure 9. Drug Reprofiling Report Years Considered Figure 10. Global Drug Reprofiling Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 11. Global Drug Reprofiling Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Drug Reprofiling Market Share by Regions: 2020 VS 2027 Figure 13. Global Drug Reprofiling Market Share by Regions (2022-2027) Figure 14. Global Drug Reprofiling Market Share by Players in 2020 Figure 15. Global Top Drug Reprofiling Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drug Reprofiling as of 2020 Figure 16. The Top 10 and 5 Players Market Share by Drug Reprofiling Revenue in 2020 Figure 17. Global Drug Reprofiling Revenue Market Share by Type (2016-2021) Figure 18. Global Drug Reprofiling Revenue Market Share by Type (2022-2027) Figure 19. North America Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 20. North America Drug Reprofiling Market Share by Type (2016-2027) Figure 21. North America Drug Reprofiling Market Share by Application (2016-2027) Figure 22. North America Drug Reprofiling Market Share by Country (2016-2027) Figure 23. United States Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Canada Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe Drug Reprofiling Market Share by Type (2016-2027) Figure 27. Europe Drug Reprofiling Market Share by Application (2016-2027) Figure 28. Europe Drug Reprofiling Market Share by Country (2016-2027) Figure 29. Germany Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. France Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. U.K. Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Italy Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Russia Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Nordic Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific Drug Reprofiling Market Share by Type (2016-2027) Figure 37. Asia-Pacific Drug Reprofiling Market Share by Application (2016-2027) Figure 38. Asia-Pacific Drug Reprofiling Market Share by Region (2016-2027) Figure 39. China Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Japan Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. South Korea Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Southeast Asia Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. India Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Australia Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America Drug Reprofiling Market Share by Type (2016-2027) Figure 47. Latin America Drug Reprofiling Market Share by Application (2016-2027) Figure 48. Latin America Drug Reprofiling Market Share by Country (2016-2027) Figure 49. Mexico Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Brazil Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa Drug Reprofiling Market Share by Type (2016-2027) Figure 53. Middle East & Africa Drug Reprofiling Market Share by Application (2016-2027) Figure 54. Middle East & Africa Drug Reprofiling Market Share by Country (2016-2027) Figure 55. Turkey Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Saudi Arabia Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. UAE Drug Reprofiling Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Novartis AG Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 59. Abbott Healthcare Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 60. Pfizer Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 61. Johnson & Johnson Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 62. Hoffmann-La Roche Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 63. Sandoz Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 64. Mylan Inc. Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Drug Reprofiling Business (2016-2021) Figure 66. Bottom-up and Top-down Approaches for This Report Figure 67. Data Triangulation Figure 68. Key Executives Interviewed

Novartis AG Abbott Healthcare Pfizer Johnson & Johnson Hoffmann-La Roche Sandoz Mylan Inc. Teva Pharmaceuticals